BeyondSpring Inc. (BYSI)

Over the past six months, BeyondSpring, Inc.'s stock price has experienced notable movements, including a surge of 56% as of October 7, 2025, and an increase of 15.36% over the last six months as of November 25, 2025. Key events impacting the stock include the Q3 2025 earnings release with a GAAP EPS of -$0.04, Q2 2025 financial results with a GAAP EPS of -$0.04, insider selling by Decheng Capital, the Annual General Meeting held on September 15, 2025, the Q1 2025 earnings release with a GAAP EPS of $0.11, the 2024 Annual Report Filing on Form 10-K on March 27, 2025 and the sale of Equity Interest in SEED Therapeutics in January 2025.

Information directly detailing the demand seasonality for BeyondSpring, Inc.'s specific products and services is not readily available. As a clinical-stage biopharmaceutical company, the demand for its products would likely be driven by clinical trial progress, regulatory approvals, and the prevalence of the targeted cancer indications, rather than traditional seasonal consumer demand.

BeyondSpring, Inc. is a global clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Founded in 2013 and headquartered in New York City, the company operates in the pharmaceuticals and healthcare industry, with a focus on oncology. Its core business segments include oncology therapeutics and drug discovery platforms, with its flagship product being Plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA). Plinabulin is being developed for multiple indications, including the prevention of chemotherapy-induced neutropenia (CIN) and as an anti-cancer agent. The company also has other pipeline products and invests in innovative drug discovery platforms.

BeyondSpring, Inc. has a global presence with operations in the United States and China. The company operates through subsidiaries located in the US, Hong Kong, China, the UK, Australia, and Brazil.

BeyondSpring's brand reputation has been influenced by positive developments related to its clinical programs and strategic collaborations. The company has reported promising clinical data for Plinabulin, including its potential to re-sensitize tumors in NSCLC patients, with presentations at major conferences. SEED Therapeutics, BeyondSpring's co-founded subsidiary, has also contributed positively, completing a $30 million Series A-3 financing and receiving FDA clearance for its lead RBM39 degrader program. The appointment of a new CFO and CBO at SEED Therapeutics also reflects positively on the company's strategic direction.

BeyondSpring, Inc.'s ownership structure includes institutional, retail, and individual investors. As of September 30, 2025, there are 18 institutional holders holding a total of 5,920,795 shares, with major institutional shareholders including Decheng Capital LLC, BlackRock, Inc., and Vanguard Group Inc. Xiangmin Cui is noted as owning the most shares of BeyondSpring Inc. Insiders collectively own approximately 22.29% of the company's stock.